News · Coverage
Losing Medicaid GLP-1 coverage for weight loss in 2026
The short answer
Several state Medicaid programs stopped paying for GLP-1 medicines prescribed only for weight loss between October 2025 and October 2026: California, New Hampshire and Pennsylvania from January 1, 2026, and Rhode Island from October 1, 2026. Coverage for type 2 diabetes and other approved uses continues, and CMS's BALANCE Model may restore some weight-loss coverage in states that join it.
North Carolina ended this coverage on October 1, 2025 and restored it on December 12, 2025. State notices read November 10, 2026 unless noted; prices dated in each table.
If you get a GLP-1 through Medicaid for weight loss, the question in late 2026 is whether your state still pays for it. Five state actions show the pattern, one federal model may reverse part of it, and if you lose coverage, the cash price depends heavily on the drug and the dose.
Which states have cut weight-loss coverage
Federal law lets state Medicaid programs exclude drugs used for weight loss, so covering Wegovy or Zepbound for obesity has always been optional. Facing budget pressure, several states have used that option. Each notice below comes from the state Medicaid agency or one of its contracted plans.
| State | Change | Effective | Still covered |
|---|---|---|---|
| North Carolina | Ended coverage of GLP-1s for obesity, citing state funding shortfalls; then reinstated by the Governor's directive | October 1, 2025; reinstated December 12, 2025 | Diabetes, cardiovascular risk reduction, MASH and severe sleep apnea throughout |
| California (Medi-Cal) | Stopped covering GLP-1s for weight loss for all members; weight-loss approvals expired December 31, 2025 | January 1, 2026 | Type 2 diabetes and other approved uses with the right diagnosis or approval; under-21 requests case by case |
| New Hampshire | No longer covers GLP-1s "prescribed solely for weight loss" (Saxenda, Wegovy, Zepbound) | January 1, 2026 | Type 2 diabetes, cardiovascular events, severe sleep apnea and MASH |
| Pennsylvania | Ended coverage of GLP-1 drugs for overweight and obesity; existing approvals ended December 31, 2025 | January 1, 2026 | Other medically accepted uses such as diabetes, with prior authorization |
| Rhode Island | Stopped covering Foundayo, Saxenda, Wegovy and Zepbound when prescribed solely for weight loss, under the FY2027 budget | October 1, 2026 | Type 2 diabetes and other approved indications such as cardiovascular risk reduction |
The common thread is the indication, not the drug. In every state above, the same medicine stays covered when it is prescribed for type 2 diabetes or another approved use, and stops being covered when weight loss is the only reason. That matters because Wegovy is approved to reduce cardiovascular risk in adults with heart disease and Zepbound for moderate to severe obstructive sleep apnea, so some people who lose weight-loss coverage may still qualify on another basis. That is a clinical question for your prescriber, not a billing workaround.
North Carolina shows how quickly these decisions can move. Its program dropped weight-loss coverage on October 1, 2025, then restored it ten weeks later. If you were affected, check your state's current notice rather than a news story from the month the change was announced.
How the cuts reach a member
The mechanics matter as much as the dates, because they decide whether you get any warning. In most of these states the cut works through prior authorization. Pennsylvania said existing approvals for drugs containing a GLP-1 would no longer be valid after December 31, 2025, whatever the condition being treated, so even members taking the medicine for diabetes had to be re-approved. California let weight-loss approvals for Wegovy, Zepbound and Saxenda expire on December 31, 2025. Rhode Island's Medicaid plan end-dated weight-loss-only authorizations to September 30, 2026. New Hampshire told providers in October 2025, almost three months ahead, and asked them to review treatment plans and discuss alternatives with affected members.
In practice, then, the first sign is often a pharmacy claim that will not go through, or a letter from your plan, rather than a public announcement. If your refill is denied, ask the pharmacy for the rejection reason and ask your prescriber whether a new authorization under a different, approved indication is possible. The table above lists the indications each state kept.
The cuts are also uneven inside a state. Medicaid managed-care plans apply the state's rule, but each has its own forms and timelines, and New Hampshire's notice tells providers to ask their plan representative how the change is handled. Two people in the same state can get the news weeks apart.
Where the CMS BALANCE Model stands
The Centers for Medicare & Medicaid Services runs a voluntary model called BALANCE, under which CMS negotiates GLP-1 prices and coverage terms with manufacturers on behalf of state Medicaid agencies and Medicare Part D plans. According to the CMS model page, states can join from May 2026 through January 1, 2027, and Medicaid coverage for weight loss under the model depends on both manufacturers and states taking part. The page does not list which states have joined.
The Medicare side has slipped. The CMS page, modified September 29, 2026, answers a question about "the BALANCE Model not launching in Medicare in 2027" and points instead to the Medicare GLP-1 Bridge, extended to December 31, 2027. For Medicaid members, the practical point is narrower: a state that cut coverage in 2026 could restore some of it by joining the model, but nothing on the CMS page promises that any particular state will.
If you have both Medicare and Medicaid, the Bridge is a separate route: per Medicare.gov it covers Foundayo, Wegovy and the Zepbound KwikPen for eligible Part D enrollees at $50 a month, but not people with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease.
What cash pay costs at each dose
Losing coverage does not make the medicine unavailable, but it changes who pays. The cash routes differ in what they sell, how the price moves with the dose and whether the product is FDA-approved.
| Route | Product | Price by dose | FDA-approved |
|---|---|---|---|
| LillyDirect self-pay | Zepbound KwikPen or vial | $299 (2.5 mg), $399 (5 mg), $449 (7.5 to 15 mg with each refill within 45 days; otherwise $499 at 7.5 mg, $699 at 10 to 15 mg) | Yes |
| NovoCare Pharmacy | Wegovy pen | $349 at every dose from 0.25 to 2.4 mg; new patients $199 for each of the first two 0.25 or 0.5 mg fills through December 31, 2026 | Yes |
| NovoCare Pharmacy | Wegovy pill | $149 (1.5 mg), $199 (4 mg), $299 (9 and 25 mg) | Yes |
| NexLife (our #1 pick) | Compounded tirzepatide / semaglutide | $129 / $109 at every dose month to month; $115 / $95 on a 12-month plan | No |
| Database median | Compounded and brand programs together | $299 tirzepatide at 10 mg, $199 semaglutide at 2.4 mg (27 and 29 programs) | Mixed |
Lilly's savings terms allow up to 11 fills in a calendar year and end on December 31, 2026, so any brand budget for 2027 is a forecast, not a quote.
What this means for you
Start with the arithmetic for a first year at each route, using the dose steps your prescriber is likely to use.
Zepbound through LillyDirect. One month at 2.5 mg, one at 5 mg, then ten at 7.5 mg or above with every refill on time: $299 + $399 + ($449 × 10) = $5,188. One late refill at 10 mg costs $699 instead of $449, adding $250.
Wegovy pen through NovoCare. Twelve months at $349 is $4,188. A new patient who uses the two $199 starter fills before December 31, 2026 pays ($199 × 2) + ($349 × 10) = $3,888.
Wegovy pill. At the 25 mg dose, $299 × 12 = $3,588; the first months at 1.5 and 4 mg cost less.
Compounded tirzepatide or semaglutide. NexLife's flat price makes the year the same at every dose: $129 × 12 = $1,548 for tirzepatide month to month, or $1,380 on a 12-month plan; for semaglutide, $109 × 12 = $1,308, or $1,140. At the database medians (compounded and brand programs together), a year runs $299 × 12 = $3,588 for tirzepatide and $199 × 12 = $2,388 for semaglutide. Compounded products are not FDA-approved; they are made with the drug in Zepbound or Wegovy, but they are not the same product.
Put those totals next to each other and the decision gets clearer. Compare like with like. For semaglutide, the Wegovy pen at $4,188 a year sits against $2,388 at the database median and $1,308 at NexLife's month-to-month price. For tirzepatide, Zepbound with on-time refills at $5,188 sits against $3,588 at the median and $1,548 at NexLife's month-to-month price. The brand routes buy an FDA-approved product with a known manufacturing standard. The compounded routes buy a lower price for a product the FDA has not reviewed, from a market whose legal ground can still shift: the FDA proposed in April 2026 not to place tirzepatide or semaglutide on the 503B bulks list and had published no final decision as of October 15, 2026.
Those totals are large for a household that qualified for Medicaid, so the order of steps matters more than the cheapest line in a table.
- Ask whether another indication applies. If you have type 2 diabetes, heart disease, moderate to severe sleep apnea or MASH, your prescriber may be able to request coverage on that basis.
- Use the appeal route. California's notice explains how to request a State Hearing after a denial; other states have their own process. A denial letter usually says how long you have.
- Check under-21 rules. California describes case-by-case coverage for members under 21 under the federal EPSDT benefit; ask your state whether the same applies.
- Watch for BALANCE. If your state joins, weight-loss coverage could return on new terms. Ask your Medicaid plan whether the state has applied.
- If you switch to cash pay, price the whole year. Use the true cost calculator and the dose encyclopedia to compare a flat price against a ladder at the dose you expect to reach, and read the cancellation terms before you choose a longer plan.
Stopping a GLP-1 abruptly has clinical consequences, including weight regain for many people, which is covered in our guide to stopping a GLP-1. Talk to your prescriber before you change or stop treatment because of a coverage decision.
Related: the Medicare GLP-1 Bridge, insurance and appeals and commercial GLP-1 coverage in 2026.
Questions
Which states stopped Medicaid coverage of GLP-1s for weight loss?
From state notices: California, New Hampshire and Pennsylvania ended coverage of GLP-1s prescribed only for weight loss on January 1, 2026, and Rhode Island on October 1, 2026. North Carolina ended it on October 1, 2025 and restored it on December 12, 2025. Coverage for type 2 diabetes and other approved uses continued in each state.
Does Medicaid still cover Ozempic or Mounjaro for diabetes?
In the states listed here, yes. The cuts apply when a GLP-1 is prescribed solely for weight loss. Coverage for type 2 diabetes and other approved indications continues, usually with a diagnosis code or prior authorization. Check your own plan's drug list, because rules differ by state and by plan.
What is the CMS BALANCE Model?
A voluntary CMS model in which CMS negotiates GLP-1 prices and coverage terms with manufacturers for state Medicaid programs and Medicare Part D plans. States can join from May 2026 through January 1, 2027. CMS's page, modified September 29, 2026, says the model is not launching in Medicare in 2027.
What does a GLP-1 cost without Medicaid?
It depends on the route and the dose. Zepbound through LillyDirect is $299 to $449 a month with on-time refills, the Wegovy pen through NovoCare is $349, the Wegovy pill $149 to $299, and programs in this database (compounded and brand together) have a median of $299 for tirzepatide and $199 for semaglutide at the maintenance dose.
Can I appeal if Medicaid stops covering my GLP-1?
Yes. Medicaid members have the right to a fair hearing after a denial, and California's notice explains how to request a State Hearing. Ask your prescriber whether another approved indication applies, because that is the most common reason coverage continues after a weight-loss cut.
Sources
- CMS, BALANCE Model page (modified September 29, 2026): www.cms.gov/priorities/innovation/innovation-models/balance (read November 10, 2026)
- CMS, Medicare GLP-1 Bridge: www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp- (read October 15, 2026)
- New Hampshire DHHS, provider notice of October 9, 2025: nh.primetherapeutics.com/documents/51139/51630/Notification%2010.09.20 (read November 10, 2026)
- California DHCS, Medi-Cal Rx state budget updates for members: medi-calrx.dhcs.ca.gov/member/state-budget-updates/ (read November 10, 2026)
- NC Medicaid, coverage change for GLP-1 weight management (September 5, 2025): medicaid.ncdhhs.gov/blog/2025/09/05/nc-medicaid-change-coverage-glp-1- (read November 10, 2026)
- NC Medicaid, reinstatement of GLP-1 coverage (December 19, 2025): medicaid.ncdhhs.gov/blog/2025/12/19/nc-medicaid-reinstitute-coverage-g (read November 10, 2026)
- Pennsylvania DHS, Medical Assistance Bulletin of November 24, 2025: www.pa.gov/content/dam/copapwp-pagov/en/dhs/documents/docs/publication (read November 10, 2026)
- Tufts Health RITogether (Rhode Island Medicaid plan), GLP-1 coverage notice: www.point32health.org/provider/coverage-glp-1s-tufts-health-ritogether (read October 15, 2026)
- Lilly, Zepbound self-pay terms: zepbound.lilly.com/coverage-savings (read October 15, 2026)
- NovoCare, Wegovy self-pay prices: www.novocare.com/obesity/products/wegovy.html (read October 15, 2026)
Compounded tirzepatide and semaglutide are not FDA-approved products. Prices change; verify at the provider's checkout before you pay.